CAMBIUM BIO LIMITED — Capital/Financing Update 2021

May 11, 2021

==> picture [159 x 33] intentionally omitted <==

12 May 2021

Company Announcements Office

Australian Securities Exchange

Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)

On 11 May 2021 , Regeneus Ltd (the " Company ") issued 3,253,982 fully paid ordinary shares in accordance with the terms of its Subscription Agreement with New Life Sciences Capital, LLC, which was announced to the market on 7[th] May 2021.

Accordingly the Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the " Corporations Act ") that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act ;

2. as at the date of this notice the Company has complied with:

   • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (b) section 674 of the Corporations Act ; and

3. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the Corporations Act ) which is required to be disclosed by the Company.

On behalf of the Board of Regeneus Ltd

==> picture [125 x 37] intentionally omitted <==

Sandra McIntosh Company Secretary

Regeneus Ltd

2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358